268 related articles for article (PubMed ID: 31399497)
21. Anthracyclines induce cardiotoxicity through a shared gene expression response signature.
Matthews ER; Johnson OD; Horn KJ; Gutiérrez JA; Powell SR; Ward MC
PLoS Genet; 2024 Feb; 20(2):e1011164. PubMed ID: 38416769
[TBL] [Abstract][Full Text] [Related]
22. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.
Ma Y; North BJ; Shu J
Mol Biol Rep; 2021 Sep; 48(9):6589-6601. PubMed ID: 34476738
[TBL] [Abstract][Full Text] [Related]
23. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
[TBL] [Abstract][Full Text] [Related]
24. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
25. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
26. Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons.
Huelsenbeck SC; Schorr A; Roos WP; Huelsenbeck J; Henninger C; Kaina B; Fritz G
J Biol Chem; 2012 Nov; 287(46):38590-9. PubMed ID: 23012366
[TBL] [Abstract][Full Text] [Related]
27. Ribosomal protein S11 influences glioma response to TOP2 poisons.
Awah CU; Chen L; Bansal M; Mahajan A; Winter J; Lad M; Warnke L; Gonzalez-Buendia E; Park C; Zhang D; Feldstein E; Yu D; Zannikou M; Balyasnikova IV; Martuscello R; Konerman S; Győrffy B; Burdett KB; Scholtens DM; Stupp R; Ahmed A; Hsu P; Sonabend AM
Oncogene; 2020 Jul; 39(27):5068-5081. PubMed ID: 32528131
[TBL] [Abstract][Full Text] [Related]
28. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK
Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671
[TBL] [Abstract][Full Text] [Related]
29. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
Hasinoff BB; Patel D; Wu X
Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
[TBL] [Abstract][Full Text] [Related]
30. Interaction model for anthracycline activity against DNA topoisomerase II.
Moro S; Beretta GL; Dal Ben D; Nitiss J; Palumbo M; Capranico G
Biochemistry; 2004 Jun; 43(23):7503-13. PubMed ID: 15182192
[TBL] [Abstract][Full Text] [Related]
31. DNA-PK inhibition extends the therapeutic effects of Top2 poisoning to non-proliferating cells, increasing activity at a cost.
Wang T; Kyle AH; Baker JHE; Liu NA; Banáth JP; Minchinton AI
Sci Rep; 2023 Aug; 13(1):12429. PubMed ID: 37528151
[TBL] [Abstract][Full Text] [Related]
32. The Deubiquitinating Enzyme Inhibitor PR-619 is a Potent DNA Topoisomerase II Poison.
Cowell IG; Ling EM; Swan RL; Brooks MLW; Austin CA
Mol Pharmacol; 2019 Nov; 96(5):562-572. PubMed ID: 31515282
[TBL] [Abstract][Full Text] [Related]
33. Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage.
Keresteš V; Kubeš J; Applová L; Kollárová P; Lenčová-Popelová O; Melnikova I; Karabanovich G; Khazeem MM; Bavlovič-Piskáčková H; Štěrbová-Kovaříková P; Austin CA; Roh J; Štěrba M; Šimůnek T; Jirkovská A
Toxicol Sci; 2024 Mar; 198(2):288-302. PubMed ID: 38290791
[TBL] [Abstract][Full Text] [Related]
34. DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation.
Dal Ben D; Palumbo M; Zagotto G; Capranico G; Moro S
Curr Pharm Des; 2007; 13(27):2766-80. PubMed ID: 17897022
[TBL] [Abstract][Full Text] [Related]
35. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Sorensen M; Sehested M; Jensen PB
Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells.
Bandele OJ; Osheroff N
Biochemistry; 2008 Nov; 47(45):11900-8. PubMed ID: 18922022
[TBL] [Abstract][Full Text] [Related]
37. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
Pommier Y; Leo E; Zhang H; Marchand C
Chem Biol; 2010 May; 17(5):421-33. PubMed ID: 20534341
[TBL] [Abstract][Full Text] [Related]
38. On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs.
Wu CC; Li YC; Wang YR; Li TK; Chan NL
Nucleic Acids Res; 2013 Dec; 41(22):10630-40. PubMed ID: 24038465
[TBL] [Abstract][Full Text] [Related]
39. Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids.
Glisson BS; Killary AM; Merta P; Ross WE; Siciliano J; Siciliano MJ
Cancer Chemother Pharmacol; 1992; 31(2):131-8. PubMed ID: 1333369
[TBL] [Abstract][Full Text] [Related]
40. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]